DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-19.23%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$384M
AUM Growth
+$384M
(-3.5%)
Cap. Flow
+$76M
Cap. Flow
% of AUM
19.81%
Top 10 Holdings %
Top 10 Hldgs %
46.53%
Holding
98
New
11
Increased
36
Reduced
12
Closed
4
Top Buys
| 1 |
SPDR S&P Biotech ETF
XBI
|
$24.2M |
| 2 |
iShares Biotechnology ETF
IBB
|
$8.03M |
| 3 |
Fate Therapeutics
FATE
|
$4.99M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$4.77M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$3.51M |
Top Sells
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$11.1M |
| 2 |
OTIC
Otonomy, Inc.
OTIC
|
$1.69M |
| 3 |
HOOK
HOOKIPA Pharma
HOOK
|
$747K |
| 4 |
Xenon Pharmaceuticals
XENE
|
$688K |
| 5 |
ProQR Therapeutics
PRQR
|
$685K |
Sector Composition
| 1 | Healthcare | 86.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Biomea Fusion
BMEA
$114M
| $1.71M | 0.45% |
383,923
+70,000
| +22% | +$312K |
|
|
RDUS
52
DELISTED
Radius Health, Inc.
RDUS
| $1.7M | 0.44% |
191,978
| – | – |
|
53
MacroGenics
MGNX
$121M
| $1.69M | 0.44% |
192,000
+102,000
| +113% | +$899K |
|
54
Cogent Biosciences
COGT
$1.83B
| $1.67M | 0.44% |
223,554
| – | – |
|
|
KNTE
55
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $1.67M | 0.43% |
148,151
+41,698
| +39% | +$469K |
|
|
RGLS
56
DELISTED
Regulus Therapeutics
RGLS
| $1.66M | 0.43% |
5,555,555
| – | – |
|
|
NGM
57
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $1.64M | 0.43% |
107,653
+27,168
| +34% | +$414K |
|
58
Immunocore
IMCR
$1.78B
| $1.61M | 0.42% |
+53,878
| New | +$1.61M |
|
|
TPTX
59
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $1.6M | 0.42% |
59,452
+13,000
| +28% | +$349K |
|
60
Mersana Therapeutics
MRSN
$34.8M
| $1.41M | 0.37% |
352,763
+212,500
| +152% | +$848K |
|
61
Venus Concept
VERO
$4.07M
| $1.39M | 0.36% |
968,187
-7,500
| -0.8% | -$10.6K |
|
|
MREO
62
Mereo BioPharma
MREO
$275M
| $1.36M | 0.36% |
1,216,613
+90,000
| +8% | +$101K |
|
63
Viking Therapeutics
VKTX
$3.02B
| $1.34M | 0.35% |
447,400
| – | – |
|
64
89bio
ETNB
$1.37B
| $1.22M | 0.32% |
324,053
+179,400
| +124% | +$677K |
|
65
MEI Pharma
MEIP
$149M
| $1.07M | 0.28% |
1,767,146
+2,300
| +0.1% | +$1.39K |
|
66
GH Research
GHRS
$870M
| $1.01M | 0.26% |
+55,000
| New | +$1.01M |
|
|
CMPS
67
Compass Pathways
CMPS
$452M
| $965K | 0.25% |
+74,890
| New | +$965K |
|
68
Neuronetics
STIM
$216M
| $951K | 0.25% |
313,717
| – | – |
|
|
THRX
69
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $924K | 0.24% |
80,124
-17,376
| -18% | -$200K |
|
70
NextCure
NXTC
$13.3M
| $912K | 0.24% |
187,696
| – | – |
|
71
Black Diamond Therapeutics
BDTX
$164M
| $869K | 0.23% |
313,600
+107,500
| +52% | +$298K |
|
72
Wave Life Sciences
WVE
$1.27B
| $780K | 0.2% |
390,161
| – | – |
|
|
GNFT
73
Genfit
GNFT
$198M
| $752K | 0.2% |
187,940
+127,492
| +211% | +$510K |
|
|
ADAP
74
Adaptimmune Therapeutics
ADAP
$13.9M
| $723K | 0.19% |
351,064
+214,798
| +158% | +$442K |
|
|
VIGL
75
DELISTED
Vigil Neuroscience
VIGL
| $701K | 0.18% |
+99,754
| New | +$701K |
|